Seres Therapeutics, Nestlé Health Science Announce SER-109 Co-Commercialization License Agreement
Companies Agree to Jointly Commercialize SER-109 Investigational Microbiome Therapeutic to Treat Recurrent C. difficile Infection, Leading the Way for Entirely New Treatment Modality Deal calls for more than $500 million
ACCELERATOR LIFE SCIENCE PARTNERS’ PORTFOLIO COMPANY LODO THERAPEUTICS ACQUIRED BY ZYMERGEN INC.
SEATTLE – (BUSINESS WIRE) – Accelerator Life Science Partners (“ALSP”), a leading early-stage life science accelerator and investment firm, today announced that its portfolio company, Lodo Therapeutics Corporation (“Lodo” or
SYNBIO POWERHOUSE GINKGO BIOWORKS GOES PUBLIC IN $17.5B SPAC DEAL
Genetic Engineering & Biotechnology News (May 11, 2021) Synthetic biology powerhouse Ginkgo Bioworks said today it will become a public company through a $17.5 billion merger with a special purpose
VEDANTA BIOSCIENCES ANNOUNCES A $25 MILLION INVESTMENT FROM PFIZER INC.
Michael Vincent, M.D., Ph.D., Chief Scientific Officer, Inflammation & Immunology Research Unit at Pfizer, to join Vedanta’s Scientific Advisory Board CAMBRIDGE, January 12, 2021 – Vedanta Biosciences, a leading clinical-stage company
GILEAD SCIENCES TO ACQUIRE KITE PHARMA FOR $11.9 BILLION
Immediately Positions Gilead as a Leader in Cell Therapy Kite’s Lead CAR T Therapy Candidate, Axicabtagene Ciloleucel, Under Priority Review in the U.S. and Expedited Review in the EU Provides